WASHINGTON — A new report out from AARP today provides additional insight into the impact of a historic new financial protection for our nation’s nearly 55 million Medicare drug plan enrollees. For the first time ever, beginning January 1, 2025, Medicare drug plans will limit enrollees’ annual out-of-pocket spending to $2,000, thanks to a provision in the 2022 Inflation Reduction Act that AARP championed. Specifically, the report shows that 94% of all Part D enrollees expected to reach the new cap in 2025 will have lower total (i.e., premiums and cost sharing) out-of-pocket costs, saving an average of $2,474 nationally. The report also provides state-level data and estimates that 95% of Part D enrollees who will reach the out-of-pocket cap will have lower out-of-pocket health costs in 33 states plus the District of Columbia.

According to a new AARP survey exploring the second half of life, most older adults have an optimistic outlook on life and expect their lives to improve as they get older. Nearly 9 in 10 are at least somewhat optimistic about their future, with half being extremely or very optimistic.

Today, AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) announcement of the first Medicare negotiated drug prices as part of the 2022 prescription drug law:

AARP CEO Jo Ann Jenkins issued the following statement in response to the Medicare and Social Security Trustees Reports released today:

Today, AARP CEO Jo Ann Jenkins issued the following statement in response to President Biden’s State of the Union address: